On Oct 17, major Wall Street analysts update their ratings for $Johnson & Johnson (JNJ.US)$, with price targets ranging from $166 to $185.
Morgan Stanley analyst Terence Flynn maintains with a hold rating, and adjusts the target price from $169 to $175.
Citi analyst Joanne Wuensch maintains with a buy rating, and adjusts the target price from $180 to $185.
Wells Fargo analyst Larry Biegelsen maintains with a hold rating, and adjusts the target price from $163 to $166.
TD Cowen analyst Josh Jennings maintains with a buy rating, and maintains the target price at $185.
Furthermore, according to the comprehensive report, the opinions of $Johnson & Johnson (JNJ.US)$'s main analysts recently are as follows:
Johnson & Johnson's third-quarter results were largely in line with market expectations, thanks to the robust performance of its Innovative Medicine business, which helped to balance the challenges within the MedTech sector. Management's early commentary on the 2025 outlook conveyed a strong belief in achieving over $57 billion in sales from Innovative Medicine. The company's growth goals for MedTech between 2024 and 2027, aiming for the higher spectrum of 5%-7%, were noted, although this target is considered to be quite optimistic.
Following a third-quarter report which aligned with general expectations, the pharmaceutical segment surpassed forecasts while the medical technology division fell short. The company's outlook for 2025 remained largely in line with prior projections, leading to slight revisions in estimates.
Following Johnson & Johnson's third-quarter report, the company's movement towards resolving talc litigation and integrating several medical technology acquisitions, along with providing 'level-set 2025 commentary,' supports a positive perspective on the shares.
Johnson & Johnson's Q3 earnings exceeded expectations, reporting a 5.6% underlying growth excluding Covid-related contributions, which was primarily fueled by performance in Innovative Medicine, while MedTech experienced a lag, partly due to seasonal variations and challenges in the Asia Pacific region. Post-Q3 results indicate that the company is making significant operational strides, particularly with the advancement of its pipeline execution.
Johnson & Johnson's sales growth forecast for 2024 suggests a slowdown in growth during Q4, yet the management's remarks about 2025 appear promising for EPS expansion. Additionally, the company is of the view that substantial headway has been achieved in dealing with the talc litigation.
Here are the latest investment ratings and price targets for $Johnson & Johnson (JNJ.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
